Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells: A Potential Mechanism for the Anticancer Properties of Tamoxifen

Zhila Khalkhali-Ellis, Abby L. Christian, Dawn A. Kirschmann, Elijah M. Edwards, Maryam Rezaie-Thompson, Mohammad A. Vasef, Lynn M. Gruman, Richard E B Seftor, Laura E. Norwood, Mary J C Hendrix

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose: Mammary epithelial cells and the majority of breast cancer tumors require estrogen for continued growth. Antiestrogen therapy alone, or in combination with other drugs, has long been a common procedure for breast cancer treatment and prophylaxis. Thus, there is a critical need to elucidate the mechanism(s) of action of antiestrogen treatment, especially for patients who are at risk of breast cancer development or who are currently receiving hormone therapy. In this study, we examined the ability of hormones to regulate the expression of a tumor suppressor gene, maspin, which is a serine protease inhibitor (serpin) that plays an important role in mammary gland development and is silenced during breast cancer progression. Specifically, our hypothesis tested the clinical efficacy of tamoxifen to regulate maspin expression. Experimental Design: We used maspin promoter luciferase reporter plasmids that were transfected into normal human mammary epithelial (HMEC1331) and MCF-7 breast cancer cells, followed by determination of the effect of hormones and their antagonists on maspin promoter activity. At the protein level, cytosolic fractions from both cell types before and after hormone treatment were subjected to Western blot analysis to determine maspin level. Results and Conclusions: Our studies revealed that the antiestrogen tamoxifen induces maspin promoter activity. Interestingly, antiandrogen flutamide could also induce maspin in both cell lines tested. These observations were further confirmed in patient tissues. These novel findings provide a new mechanism of action for tamoxifen under normal and pathological conditions. More significantly, these findings could have a potential impact on future therapeutic intervention strategies for breast cancer.

Original languageEnglish (US)
Pages (from-to)449-454
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number2
DOIs
StatePublished - Jan 15 2004
Externally publishedYes

Fingerprint

Tamoxifen
Tumor Suppressor Genes
Breast Neoplasms
Estrogen Receptor Modulators
Hormones
Breast
Therapeutics
Flutamide
Hormone Antagonists
Androgen Antagonists
Serine Proteinase Inhibitors
Human Mammary Glands
SERPIN-B5
Luciferases
Estrogens
Plasmids
Research Design
Western Blotting
Epithelial Cells
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Khalkhali-Ellis, Z., Christian, A. L., Kirschmann, D. A., Edwards, E. M., Rezaie-Thompson, M., Vasef, M. A., ... Hendrix, M. J. C. (2004). Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells: A Potential Mechanism for the Anticancer Properties of Tamoxifen. Clinical Cancer Research, 10(2), 449-454. https://doi.org/10.1158/1078-0432.CCR-1002-03

Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells : A Potential Mechanism for the Anticancer Properties of Tamoxifen. / Khalkhali-Ellis, Zhila; Christian, Abby L.; Kirschmann, Dawn A.; Edwards, Elijah M.; Rezaie-Thompson, Maryam; Vasef, Mohammad A.; Gruman, Lynn M.; Seftor, Richard E B; Norwood, Laura E.; Hendrix, Mary J C.

In: Clinical Cancer Research, Vol. 10, No. 2, 15.01.2004, p. 449-454.

Research output: Contribution to journalArticle

Khalkhali-Ellis, Z, Christian, AL, Kirschmann, DA, Edwards, EM, Rezaie-Thompson, M, Vasef, MA, Gruman, LM, Seftor, REB, Norwood, LE & Hendrix, MJC 2004, 'Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells: A Potential Mechanism for the Anticancer Properties of Tamoxifen', Clinical Cancer Research, vol. 10, no. 2, pp. 449-454. https://doi.org/10.1158/1078-0432.CCR-1002-03
Khalkhali-Ellis, Zhila ; Christian, Abby L. ; Kirschmann, Dawn A. ; Edwards, Elijah M. ; Rezaie-Thompson, Maryam ; Vasef, Mohammad A. ; Gruman, Lynn M. ; Seftor, Richard E B ; Norwood, Laura E. ; Hendrix, Mary J C. / Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells : A Potential Mechanism for the Anticancer Properties of Tamoxifen. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 2. pp. 449-454.
@article{532de9e51c1949f2926f024a7a19f557,
title = "Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells: A Potential Mechanism for the Anticancer Properties of Tamoxifen",
abstract = "Purpose: Mammary epithelial cells and the majority of breast cancer tumors require estrogen for continued growth. Antiestrogen therapy alone, or in combination with other drugs, has long been a common procedure for breast cancer treatment and prophylaxis. Thus, there is a critical need to elucidate the mechanism(s) of action of antiestrogen treatment, especially for patients who are at risk of breast cancer development or who are currently receiving hormone therapy. In this study, we examined the ability of hormones to regulate the expression of a tumor suppressor gene, maspin, which is a serine protease inhibitor (serpin) that plays an important role in mammary gland development and is silenced during breast cancer progression. Specifically, our hypothesis tested the clinical efficacy of tamoxifen to regulate maspin expression. Experimental Design: We used maspin promoter luciferase reporter plasmids that were transfected into normal human mammary epithelial (HMEC1331) and MCF-7 breast cancer cells, followed by determination of the effect of hormones and their antagonists on maspin promoter activity. At the protein level, cytosolic fractions from both cell types before and after hormone treatment were subjected to Western blot analysis to determine maspin level. Results and Conclusions: Our studies revealed that the antiestrogen tamoxifen induces maspin promoter activity. Interestingly, antiandrogen flutamide could also induce maspin in both cell lines tested. These observations were further confirmed in patient tissues. These novel findings provide a new mechanism of action for tamoxifen under normal and pathological conditions. More significantly, these findings could have a potential impact on future therapeutic intervention strategies for breast cancer.",
author = "Zhila Khalkhali-Ellis and Christian, {Abby L.} and Kirschmann, {Dawn A.} and Edwards, {Elijah M.} and Maryam Rezaie-Thompson and Vasef, {Mohammad A.} and Gruman, {Lynn M.} and Seftor, {Richard E B} and Norwood, {Laura E.} and Hendrix, {Mary J C}",
year = "2004",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-1002-03",
language = "English (US)",
volume = "10",
pages = "449--454",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Regulating the Tumor Suppressor Gene Maspin in Breast Cancer Cells

T2 - A Potential Mechanism for the Anticancer Properties of Tamoxifen

AU - Khalkhali-Ellis, Zhila

AU - Christian, Abby L.

AU - Kirschmann, Dawn A.

AU - Edwards, Elijah M.

AU - Rezaie-Thompson, Maryam

AU - Vasef, Mohammad A.

AU - Gruman, Lynn M.

AU - Seftor, Richard E B

AU - Norwood, Laura E.

AU - Hendrix, Mary J C

PY - 2004/1/15

Y1 - 2004/1/15

N2 - Purpose: Mammary epithelial cells and the majority of breast cancer tumors require estrogen for continued growth. Antiestrogen therapy alone, or in combination with other drugs, has long been a common procedure for breast cancer treatment and prophylaxis. Thus, there is a critical need to elucidate the mechanism(s) of action of antiestrogen treatment, especially for patients who are at risk of breast cancer development or who are currently receiving hormone therapy. In this study, we examined the ability of hormones to regulate the expression of a tumor suppressor gene, maspin, which is a serine protease inhibitor (serpin) that plays an important role in mammary gland development and is silenced during breast cancer progression. Specifically, our hypothesis tested the clinical efficacy of tamoxifen to regulate maspin expression. Experimental Design: We used maspin promoter luciferase reporter plasmids that were transfected into normal human mammary epithelial (HMEC1331) and MCF-7 breast cancer cells, followed by determination of the effect of hormones and their antagonists on maspin promoter activity. At the protein level, cytosolic fractions from both cell types before and after hormone treatment were subjected to Western blot analysis to determine maspin level. Results and Conclusions: Our studies revealed that the antiestrogen tamoxifen induces maspin promoter activity. Interestingly, antiandrogen flutamide could also induce maspin in both cell lines tested. These observations were further confirmed in patient tissues. These novel findings provide a new mechanism of action for tamoxifen under normal and pathological conditions. More significantly, these findings could have a potential impact on future therapeutic intervention strategies for breast cancer.

AB - Purpose: Mammary epithelial cells and the majority of breast cancer tumors require estrogen for continued growth. Antiestrogen therapy alone, or in combination with other drugs, has long been a common procedure for breast cancer treatment and prophylaxis. Thus, there is a critical need to elucidate the mechanism(s) of action of antiestrogen treatment, especially for patients who are at risk of breast cancer development or who are currently receiving hormone therapy. In this study, we examined the ability of hormones to regulate the expression of a tumor suppressor gene, maspin, which is a serine protease inhibitor (serpin) that plays an important role in mammary gland development and is silenced during breast cancer progression. Specifically, our hypothesis tested the clinical efficacy of tamoxifen to regulate maspin expression. Experimental Design: We used maspin promoter luciferase reporter plasmids that were transfected into normal human mammary epithelial (HMEC1331) and MCF-7 breast cancer cells, followed by determination of the effect of hormones and their antagonists on maspin promoter activity. At the protein level, cytosolic fractions from both cell types before and after hormone treatment were subjected to Western blot analysis to determine maspin level. Results and Conclusions: Our studies revealed that the antiestrogen tamoxifen induces maspin promoter activity. Interestingly, antiandrogen flutamide could also induce maspin in both cell lines tested. These observations were further confirmed in patient tissues. These novel findings provide a new mechanism of action for tamoxifen under normal and pathological conditions. More significantly, these findings could have a potential impact on future therapeutic intervention strategies for breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=10744226303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744226303&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-1002-03

DO - 10.1158/1078-0432.CCR-1002-03

M3 - Article

C2 - 14760064

AN - SCOPUS:10744226303

VL - 10

SP - 449

EP - 454

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -